NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

09:10pm Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
21/26/21	€0.5500	-1.79%	27,063
20/26/20	€0.5600	-3.28%	23,137
19/26/19	€0.5790	+2.12%	18,414
16/26/16	€0.5670	-1.90%	27,495
15/26/15	€0.5780	-0.86%	36,369

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - NFL Biosciences

Company calendar

Market Closed - Euronext Paris 09:25:00 21/10/2026 pm IST			5-day change	1st Jan Change
0.5500 ^EUR	-1.79%		-5.66%	-53.31%

19/10	This week's earnings calendar: CAC stocks, Meta, Tesla, SAP and Nestlé in the spotlight
06/10	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI

Market Cap	69.7L 78.21L 64.53L 58.4L 1.1Cr 74Cr 1.11Cr 7.74Cr 3.04Cr 39Cr 2.93Cr 2.87Cr 123.63Cr	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	53.5L 60.04L 49.53L 44.83L 84.46L 57Cr 85.46L 5.94Cr 2.33Cr 30Cr 2.25Cr 2.21Cr 95Cr	EV / Sales 2024	3,70,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	ALNFL	Real-time
Deutsche Boerse AG	82F	Delayed
Börse Stuttgart	82F	Delayed

19/10	This week's earnings calendar: CAC stocks, Meta, Tesla, SAP and Nestlé in the spotlight
06/10	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI
28/07	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07/07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
30/06	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
30/06	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
02/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
01/06	NFL Biosciences validates breakthrough in personalized medicine
26/05	Glimmers of hope for Middle East peace grow brighter
26/05	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
25/05	NFL Biosciences files new patent application
25/05	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
12/05	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI

NFL Biosciences Share Price

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news: NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Price Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

20/25/20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
02/24/02	NFL Biosciences: Invest Securities reduces its target
15/24/15	NFL Biosciences: Invest Securities raises its target

06/10	NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation	BU
08/09	NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie	BU
28/07	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
07/07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
30/06	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU

21/10	Agenda Zonebourse des résultats de sociétés : le 22 octobre 2026
19/10	Agenda Zonebourse des résultats de sociétés : semaine du 19 au 23 octobre 2026
17/10	Agenda des résultats de la semaine : valeurs du CAC, Meta, Tesla, SAP et Nestlé en piste
16/10	Agenda Zonebourse des résultats de sociétés : semaine du 19 au 23 octobre 2026
06/10	NFL Biosciences : point d’étape en vue des prochains jalons créateurs de valeur pour ses deux programmes cliniques dans le sevrage tabagique

1 day	-1.79%
1 week	-5.66%
Current month	-20.29%
1 month	-24.76%
3 months	-34.91%
6 months	-48.21%
Current year	-53.31%

1 week	0.53	0.58
1 month	0.53	0.76
Current year	0.53	1.85
1 year	0.53	1.85
3 years	0.53	3.28
5 years	0.53	4
10 years	0.53	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	17/10/2024
Guillaume Audema DFI	Director of Finance/CFO	-	01/01/2022
Yannick Plétan CTO	Chief Tech/Sci/R&D Officer	-	17/10/2024

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	27/02/2023
Bruno Lafont CHM	Chairman	-	17/10/2024
Francis Ahner BRD	Director/Board Member	-	19/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-1.79%	-5.66%	-52.17%	-50.81%	79.73L
WUXI APPTEC CO., LTD.	-0.21%	-6.36%	+49.00%	+74.13%	6.63TCr
LONZA GROUP AG	-0.22%	+6.53%	+11.68%	+87.32%	5.29TCr
ARGENX SE	+0.82%	+5.41%	+8.05%	+73.53%	5.48TCr
IQVIA HOLDINGS INC.	+3.28%	+5.58%	+26.51%	+50.05%	4.41TCr
BEONE MEDICINES AG	+0.51%	+9.95%	+22.40%	+133.92%	4.37TCr
REVOLUTION MEDICINES, INC.	-1.15%	+0.39%	+263.21%	+594.60%	4.21TCr
CELLTRION, INC.	+0.10%	+9.90%	+16.11%	+59.33%	3.4TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.30%	-0.68%	+37.15%	+7.16%	2.62TCr
GENMAB A/S	+0.69%	+5.60%	+36.60%	+26.94%	2.34TCr
Average	+0.07%	+3.70%	+41.85%	+105.62%	3.88TCr
Weighted average by Cap.	+0.32%	+4.54%	+51.41%	+127.77%

	2024	2025
Net sales	46 51.62 42.59 38.54 72.61 4.87T 73.47 510.62 200.36 2.56T 193.65 189.62 8.16T	188 210.98 174.06 157.52 296.76 19.91T 300.28 2.09T 818.86 10.46T 791.43 774.95 33.35T
Net income	-20.81L -23.35L -19.27L -17.43L -32.85L -22Cr -33.24L -2.31Cr -90.63L -12Cr -87.6L -85.77L -37Cr	-33.18L -37.23L -30.72L -27.8L -52.38L -35Cr -53L -3.68Cr -1.45Cr -18Cr -1.4Cr -1.37Cr -59Cr
Net Debt	-20.73L -23.26L -19.19L -17.36L -32.72L -22Cr -33.1L -2.3Cr -90.27L -12Cr -87.25L -85.43L -37Cr	-16.19L -18.17L -14.99L -13.57L -25.56L -17Cr -25.87L -1.8Cr -70.54L -9.01Cr -68.17L -66.75L -29Cr